康方生物能够成为医药黑马股，最主要的推动力是其研发的双抗依沃西（AK112）获得海外药厂50亿美元授权款，以及该产品头对头试验击败全球销售“药王”K药。此外，公司多款产品已经商业化上市，推动营收快速增长，研发管线储备丰富，未来前景被市场看好，但公司仍待盈利。2025年以来，港股创新药指数表现强劲，年初至今涨幅37.7%。板块中的不少个股更是连创新高，走出主升浪行情。康方生物（09926.HK）作为...
Source Link康方生物能够成为医药黑马股，最主要的推动力是其研发的双抗依沃西（AK112）获得海外药厂50亿美元授权款，以及该产品头对头试验击败全球销售“药王”K药。此外，公司多款产品已经商业化上市，推动营收快速增长，研发管线储备丰富，未来前景被市场看好，但公司仍待盈利。2025年以来，港股创新药指数表现强劲，年初至今涨幅37.7%。板块中的不少个股更是连创新高，走出主升浪行情。康方生物（09926.HK）作为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.